Search

Search Results

1. Stereotactic Body Radiation Therapy Salvage for Lymph Node Recurrent Prostate Cancer in the Era of PSMA PET Imaging

   Purpose of Review

   Our understanding of patterns of prostate cancer recurrence after primary treatment of localized disease has significantly evolved...

   Omar E. Hayek, Soroush Rais-Bahrami, ... Samuel J. Galgano in Current Urology Reports

   Article 03 July 2023

2. The expanding role of radiation oncology across the prostate cancer continuum

   Radiotherapy is used in the treatment of prostate cancer in a variety of disease states with significant reliance on imaging to guide clinical...

   Sasha Swensen, Jay J. Liao, ... Emily S. Weg in Abdominal Radiology

   Article 20 June 2024
   

3. Salvage Robot-Assisted Radical Prostatectomy (sRARP) for Radiation-Recurrent Prostate Cancer: a Single-Center Experience

   This case series reported on five patients with radiation-recurrent localized prostate cancer (PCa) who underwent salvage robot-assisted radical...

   Shugo Yajima, Yasukazu Nakanishi, ... Hitoshi Masuda in Indian Journal of Surgical Oncology

   Article 25 November 2022

4. Reirradiation salvage radiotherapy for recurrent prostate cancer after primary low-dose brachytherapy

   Purpose

   Local recurrence of prostate cancer after low-dose rate brachytherapy is a clinical problem with limited salvage treatment options. This...

   Óscar Muñoz Muñoz, Elías Gomis Sellés, ... Patricia Cabrera Roldán in Clinical and Translational Oncology

   Article 06 September 2023
   

5. Updates on Management of Biochemical Recurrent Prostate Cancer

   Patients with biochemical recurrent prostate cancer (BCR) are a heterogeneous group, whereby a personalized approach to management is critical....

   Lauren Folgosa Cooley, Abhishek Srivastava, Neal D. Shore in Current Treatment Options in Oncology

   Article 03 January 2024

6. Evaluation of ⁶⁸Ga-PSMA-11 PET/CT: a Phase 1 clinical study in Japanese patients with primary, recurrent, or suspected recurrent prostate cancer

   Background

   Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals allow whole-body imaging to detect prostate cancer (PC). Positron...

   Anri Inaki, Atsushi Mizokami, ... Seigo Kinuya in Annals of Nuclear Medicine

   Article Open access 16 May 2024
   

7. Digital PET for recurrent prostate cancer: how the technology help

   Digital PET is characterized by high sensitivity, spatial and temporal resolution, with growing applications of this technology both in clinical...

   Maria Ricci, Bruno Carabellese, ... Andrea Cimini in Clinical and Translational Imaging

   Article 17 February 2023

8. Overview of Radiation Therapy in the Management of Localized and Metastatic Prostate Cancer

   Purpose of Review

   The goal is to describe the evolution of radiation therapy (RT) utilization in the management of localized and metastatic prostate...

   Malcolm D. Mattes in Current Urology Reports

   Article 11 June 2024

9. Health-related quality of life following salvage radical prostatectomy for recurrent prostate cancer after radiotherapy or focal therapy

   Background

   Salvage radical prostatectomy (sRP) is an important treatment option for patients with recurrent prostate cancer (PCa) after radiotherapy...

   Severin Rodler, Dina Danninger, ... Thilo Westhofen in World Journal of Urology

   Article Open access 18 April 2024
   

10. Comparative analysis of robot-assisted and open approach for PSMA-radioguided surgery in recurrent prostate cancer

    Purpose

    To compare the oncological and surgical outcomes of patients with recurrent prostate cancer (PCa) who underwent either open or newly...

    Francesca Ambrosini, Fabian Falkenbach, ... Tobias Maurer in European Journal of Nuclear Medicine and Molecular Imaging

    Article Open access 13 October 2023
    

11. Stereotactic reirradiation with Cyberknife^R for locally recurrent prostate cancer, long-term toxicity and clinical outcomes from a monocentric cohort

    Purpose

    Up to 47% of patients with localized prostate cancer (PCa) treated with radiotherapy (EBRT) eventually develop local recurrence. To date, no...

    Giulio Francolini, Maria Grazia Carnevale, ... Lorenzo Livi in La radiologia medica

    Article 20 September 2023
    

12. Recurrent prostate cancer: combined role for MRI and PSMA-PET in ⁶⁸Ga-PSMA-11 PET/MRI

    Objectives

    To investigate the specific strengths of MRI and PET components in ⁶⁸ Ga-PSMA-11 PET/MRI for staging of patients with biochemically...

    Kai Jannusch, Nils Martin Bruckmann, ... Julian Kirchner in European Radiology

    Article Open access 01 December 2023
    

13. Salvage irreversible electroporation for radio-recurrent prostate cancer

    Matthijs J. Scheltema, Athos Katelaris, Phillip D. Stricker in Nature Reviews Urology

    Article 01 March 2023
    

14. Total-body [⁶⁸ Ga]Ga-PSMA-11 PET/CT improves detection rate compared with conventional [⁶⁸ Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer

    Purpose

    The purpose of this study was to assess whether total-body [ ⁶⁸ Ga]Ga-PSMA-11 PET/CT could improve the detection rate compared with...

    Yining Wang, Zijun Chen, ... Jianjun Liu in European Journal of Nuclear Medicine and Molecular Imaging

    Article 14 August 2023
    

15. Management of bone metastasis in prostate cancer

    Progression of bone metastases is the primary cause of death in prostate cancer, and skeletal-related events (SREs), including pathologic fractures,...

    Kazuo Nishimura in Journal of Bone and Mineral Metabolism

    Article 10 May 2023
    

16. Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part II: prostate cancer and colorectal cancer

    Oligometastatic disease (OMD) defines a status of cancer that is intermediate between localized and widely spread metastatic disease, and can be...

    Antonio José Conde-Moreno, Aránzazu González-del-Alba, ... José Ángel Arranz Arija in Clinical and Translational Oncology

    Article 16 December 2022
    

17. Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) of prostate cancer: current and emerging applications

    Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) is transforming the management of patients with prostate cancer. In...

    Shamus Moran, Heather H. Cheng, ... Joseph E. Ippolito in Abdominal Radiology

    Article 22 February 2024
    

18. Vaccines as treatments for prostate cancer

    Prostate cancer is a leading cause of death in men worldwide. For over 30 years, growing interest has focused on the development of vaccines as...

    Ichwaku Rastogi, Anusha Muralidhar, Douglas G. McNeel in Nature Reviews Urology

    Article 06 March 2023
    

19. Management of the Devastated Bladder Outlet after Prostate CANCER Treatment

    Purpose of Review

    Devastating complications of the bladder outlet resulting from prostate cancer treatments are relatively uncommon. However, the...

    Francisco E. Martins, Nicolaas Lumen, Henriette Veiby Holm in Current Urology Reports

    Article 16 May 2024
    

20. Anti-Androgen Therapy Overcomes the Time Delay in Initiation of Salvage Radiation Therapy and Rescues the Oncological Outcomes in Men with Recurrent Prostate Cancer After Radical Prostatectomy: A Post Hoc Analysis of the RTOG-9601 Trial Data

    Background

    It is unknown whether the addition of anti-androgen therapy (AAT) to late salvage radiation therapy (sRT) can lead to oncological outcomes...

    Akshay Sood, Jacob Keeley, ... Firas Abdollah in Annals of Surgical Oncology

    Article 24 May 2022